HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Björn C Knollmann Selected Research

Calsequestrin

1/2018Accentuated vagal antagonism paradoxically increases ryanodine receptor calcium leak in long-term exercised Calsequestrin2 knockout mice.
3/2015Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex1.
4/2014Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts.
2/2013Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.
8/2012Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.
3/2012Calsequestrin 2 and arrhythmias.
1/2012Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background.
4/2011Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
2/2010Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
1/2010The calsequestrin mutation CASQ2D307H does not affect protein stability and targeting to the junctional sarcoplasmic reticulum but compromises its dynamic regulation of calcium buffering.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Björn C Knollmann Research Topics

Disease

22Cardiac Arrhythmias (Arrythmia)
10/2021 - 09/2007
20Polymorphic catecholergic ventricular tachycardia
10/2022 - 04/2009
7Ventricular Tachycardia
07/2013 - 03/2003
6Cardiac Sudden Death (Sudden Cardiac Arrest)
11/2011 - 03/2006
5Familial Hypertrophic Cardiomyopathy (Cardiomyopathy, Familial Hypertrophic)
07/2012 - 03/2003
4Sudden Death
03/2014 - 03/2003
3Long QT Syndrome
01/2022 - 03/2014
3Heart Diseases (Heart Disease)
04/2020 - 11/2011
3Atrial Fibrillation
01/2020 - 04/2014
3Heart Failure
01/2019 - 08/2011
3Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
01/2019 - 12/2008
2Tachycardia (Tachyarrhythmias)
10/2021 - 07/2012
2Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/2019 - 08/2011
2Fibrosis (Cirrhosis)
03/2015 - 03/2003
2Myocardial Infarction
07/2013 - 07/2012
2Premature Cardiac Complexes (Extrasystoles)
04/2013 - 02/2013
2Cardiomegaly (Heart Hypertrophy)
03/2006 - 03/2003
1Diabetic Cardiomyopathies
10/2022
1Arrhythmogenic Right Ventricular Dysplasia (Arrhythmogenic Right Ventricular Cardiomyopathy)
10/2022
1Channelopathies
01/2019
1Cardiomyopathies (Cardiomyopathy)
01/2019
1Cardiotoxicity
12/2015
1Ventricular Fibrillation
02/2014
1Infarction (Infarctions)
07/2013
1Blister (Bulla)
07/2013
1Heart Arrest (Cardiac Arrest)
04/2013
1Syncope (Fainting)
04/2013
1Reperfusion Injury
07/2012
1Ischemia
07/2012
1Hypertension (High Blood Pressure)
08/2011
1Inborn Genetic Diseases (Disease, Hereditary)
01/2010
1Diastolic Heart Failure
03/2006
1Hypertrophy
03/2003
1Substance-Related Disorders (Drug Abuse)
07/2002
1Poisoning
07/2002
1Drug-Related Side Effects and Adverse Reactions
07/2002

Drug/Important Bio-Agent (IBA)

14Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA
10/2022 - 01/2009
12CalsequestrinIBA
01/2018 - 09/2007
7CalciumIBA
04/2020 - 01/2012
7Flecainide (Tambocor)FDA LinkGeneric
01/2015 - 04/2009
6Troponin T (Troponin T1)IBA
01/2019 - 03/2003
5Calmodulin (Calcium-Dependent Activator Protein)IBA
12/2020 - 08/2011
5Trinitrotoluene (TNT)IBA
01/2019 - 03/2003
2Anti-Arrhythmia AgentsIBA
10/2021 - 04/2011
2Phosphotransferases (Kinase)IBA
01/2020 - 08/2011
2Adrenergic Agents (Adrenergic Drugs)IBA
01/2020 - 11/2011
2Proteins (Proteins, Gene)FDA Link
01/2019 - 09/2007
2CatecholaminesIBA
01/2018 - 02/2013
2Pharmaceutical PreparationsIBA
12/2015 - 05/2013
2Propafenone (Rythmol)FDA LinkGeneric
04/2014 - 07/2012
2blebbistatinIBA
07/2013 - 12/2008
2triadinIBA
05/2013 - 05/2009
2RyanodineIBA
04/2013 - 01/2009
2EMD 53998IBA
07/2012 - 12/2008
11- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
10/2022
1FructoseIBA
10/2022
1Indicators and Reagents (Reagents)IBA
10/2022
1BuffersIBA
10/2022
1phospholambanIBA
10/2022
1Potassium Channels (Potassium Channel)IBA
01/2022
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2020
1Adrenergic Receptors (Adrenergic Receptor)IBA
01/2019
1erythromycin propionate-N-acetylcysteinateIBA
01/2019
1Biological ProductsIBA
01/2019
1Vidarabine (Vira-A)FDA Link
01/2018
1Adenylyl Cyclases (Adenylyl Cyclase)IBA
01/2018
1Dantrolene (Dantrium)FDA LinkGeneric
02/2014
1Polyvinyl Chloride (PVC)IBA
07/2013
1AtropineFDA LinkGeneric
02/2013
1TeaIBA
11/2012
1Fura-2 (Fura 2)IBA
07/2012
1TroponinIBA
07/2012
1Lidocaine (Xylocaine)FDA LinkGeneric
07/2012
1Protein Isoforms (Isoforms)IBA
03/2012
1Adrenergic Antagonists (Antiadrenergic Agents)IBA
11/2011
1SodiumIBA
08/2011
1Angiotensin IIIBA
08/2011
1NADPH Oxidases (NAD(P)H oxidase)IBA
08/2011
1Histidine (L-Histidine)FDA Link
01/2010
1Amitriptyline (Elavil)FDA LinkGeneric
01/2009
1Diltiazem (Cardizem)FDA LinkGeneric
03/2006
1Isoproterenol (Isoprenaline)FDA LinkGeneric
03/2006

Therapy/Procedure

9Therapeutics
10/2021 - 02/2008
3Drug Therapy (Chemotherapy)
05/2011 - 04/2009
2Ligation
07/2013 - 07/2012
1Transplantation
10/2021
1Precision Medicine
01/2019
1Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
11/2011
1Pain Management
07/2002